15-min delayed · Sep 9, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Enlivex Therapeutics Ltd, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $13.00 to $80.00 (about 6.2x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $46.50 sits 4350% above the current $1.04. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.31 next quarter toward $-0.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Enlivex Therapeutics Ltd.
As of Sep, 1 of 2 firms rate ENLV a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ENLV EPS & revenue forecast
EPS · NEXT QUARTER
$-0.31
Range $-0.31 – $-0.31 · 1 analysts · -74% YoY
Next period, 1 analysts expect Enlivex Therapeutics Ltd to earn $-0.31 a share (range $-0.31 – $-0.31), versus $-1.20 a year earlier. Full-year consensus is $-1.15, growing to $-0.21 the year after.
REVENUE · NEXT QUARTER
—
Range — – — · 1 analysts
Revenue is expected to reach — (range — – —). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Enlivex Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ENLV.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Buy
$80.00+7555.5% to target
Overall win rate
36%
+ Follow
#2
Jason Kolbert
D. Boral Capital · Rank #416
Hold
No targeton ENLV
Overall win rate
22%
+ Follow
#3
Jason Kolbert
EF Hutton
Buy
$13.00+1144.0% to target
Coverage
—
+ Follow
#4
RS
Ram Selvaraju
H.C. Wainwright
Buy
$20.00+1813.9% to target
Coverage
—
+ Follow
ENLV stock forecast FAQ
What is ENLV's average 12-month price target?+
The 1 analysts with a live target average $46.50 for Enlivex Therapeutics Ltd over the next 12 months, ranging from a $80.00 high to a $13.00 low.
Is ENLV stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ENLV?+
The Street-high target is $80.00 (HC Wainwright & Co.), and the Street-low is $13.00. The average of all 1 active targets is $46.50.
How many Wall Street analysts cover ENLV?+
2 analysts have an active rating on Enlivex Therapeutics Ltd, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering ENLV?+
Among analysts who currently cover ENLV, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #312). Their current call is Buy with a $80.00 target.
What is Enlivex Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.31 per share (range $-0.31 – $-0.31) across 1 analysts. Full-year EPS is projected at $-1.15, rising to $-0.21 the following year.
How much revenue is Enlivex Therapeutics Ltd expected to report next quarter?+
Consensus revenue is — (range — – —). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ENLV lately?+
As of Sep, 1 of 2 firms rate ENLV a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ENLV calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
